TP53 and triple-negative breast carcinoma: In a study by Riva et al., serial levels of ctDNA containing TP53 mutations corresponded with response to neoadjuvant chemotherapy with 100% accuracy in patients with nonmetastatic, triple-negative breast cancer [34].